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ntiplatelet therapy is the cornerstone for both primary and secondary prevention therapies
or ischemic events resulting from coronary atherosclerotic disease. Dual antiplatelet therapy
aspirin plus a thienopyridine, usually clopidogrel) has assumed a central role in the treatment of
cute coronary syndromes and after coronary stent deployment. In addition to antiplatelet
herapy, anticoagulant therapy might be indicated for stroke prevention in a variety of conditions
hat include atrial fibrillation, profound left ventricular dysfunction, and after mechanical
rosthetic heart valve replacement. For this reason, the use of triple antithrombotic therapy
a dual antiplatelet regimen plus warfarin) is expected to become more prominent, given an
ging patient population. But although triple therapy can prevent both thromboembolism and
tent thrombosis, it is also associated with significant bleeding hazards. Furthermore, when
leeding events do occur, the challenge of balancing the risk of stent thrombosis or stroke
nd the need for hemostasis requires considerable expertise. It is both prudent and timely to
eview treatment strategies that employ combinations of antiplatelet and anticoagulant
herapies as well as strategies aimed at reducing bleeding risk in patients treated with these
herapies.
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rs’ Burvidence-based medicine serves as the cornerstone for
mplementing and refining optimal strategies of care.
ut as the number and complexity of therapies in-
rease in the context of an aging patient population
with an attendant admixture of coexistent diseases),
he potential for significant adverse interactions
rows. This is of particular concern in the setting of
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ptimizing outcomes in the setting of combined
ntiplatelet and anticoagulant therapy.
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ntiplatelet Therapy for
oronary Atherosclerotic Disease
ntiplatelet therapy is widely used for secondary prevention
f ischemic events associated with established coronary
therosclerotic disease (CAD) (1). In the Antithrombotic
rialists Collaboration Group meta-analysis, which exam-
ned 287 studies (comprising 135,000 patients) and com-
ared antiplatelet therapy versus control in high-risk pa-
ients (2), antiplatelet therapy was shown to reduce the
ccurrence of nonfatal myocardial infarction (MI), nonfatal
troke, or vascular death. In patients with acute MI, the
mmediate administration of aspirin (ASA) has been shown
ince the 1980s to lower the rate of periprocedural MI and
ubsequently has become both a quality-of-care metric and
Class I indication in practice guidelines (American College
f Cardiology/American Heart Association/Society for Car-
iac Angiography and Interventions [ACC/AHA/SCAI] as
ell as the European Society of Cardiology [ESC]), as
utlined in Table 1 (3–5). These guidelines recommend
rolonged dual antiplatelet therapy for at least 12 months
fter placement of drug-eluting stents (DES).
The optimal dose of ASA for acute and long-term
reatment is less well-established. Aspirin-dosing regimen
as important implications for bleeding, particularly in
atients receiving “triple therapy” (2 antiplatelet agents plus
arfarin). A wide range of doses has been evaluated, from
5 mg/day to as high as 1,500 mg/day (1,2). It has been
uggested that a dose of 75 to 162 mg/day might be more
ffective than higher doses, on the basis of potentially
dverse effects of higher doses on the production of the
asodilator prostacyclin (PGI2). In the Antithrombotic
rialists’ Collaboration (2), no statistically significant dif-
Table 1
ACC/AHA/SCAI and ESC Recommendations fo
Timing ACC/AHA/SCAI
Before PCI Patients already taking daily long-term aspirin should take 75
mg of aspirin before PCI is performed (Class I, LOE: A)
Patients not already taking long-term aspirin should be given 3
325 mg of aspirin at least 2 h and preferably 24 h before P
(Class I, LOE: C)
After PCI If a bare-metal stent has been placed, aspirin 162 to 325 mg
should be given for at least 1 month, and then daily long-te
aspirin should be continued indefinitely at doses of 75 to 1
(Class I, LOE: B)
ata from Antman et al. (3), King et al. (4), and Silber et al. (5).
ACC/AHA/SCAI  American College of Cardiology/American Heart Association/Society for Ca
CI  percutaneous coronary intervention.erences in clinical outcomes were observed between trials
hat directly compared doses of ASA 75 mg/day versus
75 mg/day. With a random effects model assessing the
ffects of ASA on mortality at 30 days, the odds ratio (OR)
or the overall population was 0.82 (95% confidence interval
CI]: 0.71 to 0.96). Among post-infarction patients, the
R was 0.86 (95% CI: 0.73 to 1.00), whereas among
atients with unstable angina the OR was 0.61 (95% CI:
.40 to 0.94). However, as the authors point out, doses75
g have been less widely studied than doses of 75 to 150
g. In general, higher ASA doses are associated with
ncreased bleeding. The optimal ASA dose regimens re-
uired for primary versus secondary prevention or for stable
ersus unstable coronary syndromes remain controversial.
Kong et al. (6) evaluated the optimal dose of ASA in the
etting of acute coronary syndrome (ACS) in a meta-
nalysis of trials with ASA doses ranging from 300 mgm to
.5 mg/day. With a variety of modeling techniques to adjust
or differences in patient and temporal characteristics, they
ound that when the effects of an ASA dose were consid-
red, the odds of death or MI increased 1.14-fold for each
oubling of the dose, suggesting “that higher doses of
spirin produced less benefit after adjusting for temporal
rends” (6).
Recently, results from the retrospective observational
RAVO (Blockade of the IIb/IIIa Receptor to Avoid
ascular Occlusion) trial were used to evaluate the relation-
hip between prescribed ASA dose (162 mg/day vs.162
g/day) and clinical outcomes in 4,589 patients who
resented with a variety of acute ischemic syndromes
unstable angina [UA] or MI within 14 days, transient
schemic attack within 30 days, stroke within 5 to 30 days)
r who had clinical involvement of 2 vascular beds with
therosclerosis (7). Clinical outcomes were analyzed to 366
spirin Administration
Recommendations
ESC
Patients not already taking daily aspirin should be given a loading
dose of 500 mg orally 3 h before procedure or 300 mg
intravenously directly before the procedure (Class I, LOE: B)
For chronic use, there is no need for doses higher than 100 mg daily
(Class I, LOE: B)
ngiography and Interventions; ESC  European Society of Cardiology; LOE  level of evidence;r A
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igher doses of ASA predicted both lower all-cause mor-
ality as well as an elevated risk of bleeding (15.3% vs.
1.2%, p  0.0001). Higher-dose ASA was not associated
ith a significant difference in the composite end point of
eath, nonfatal MI, or nonfatal stroke (6.1% vs. 6.2%, p 
.74) when compared with lower doses.
The major hazard of ASA is bleeding (1,2,6–10). The
ntithrombotic Trialists’ Collaboration (2) identified a
roportional increased risk of major extracranial bleeding
ith antiplatelet therapy (OR: 1.6, 95% CI: 1.4 to 1.8), but
nly the excess of nonfatal bleeding was significant. Other
tudies have demonstrated that ASA doses of325 mg/day
re associated with a 2-fold increase in gastrointestinal
GI) bleeding events compared with doses 325 mg (8). In
pooled analysis of 55 randomized controlled trials (RCTs)
9), 75,005 patients were treated with low-dose ASA versus
lacebo. Among patients given placebo, the weighted inci-
ence of any major bleeding was 0.18%/year, and the
bsolute rate increase with ASA above placebo was 0.13%/
ear. The weighted incidence of major GI bleeding with
lacebo was 0.12%/year, and the absolute rate of increase
ith ASA above placebo was 0.12%/year. Finally, among
lacebo-treated patients, the weighted incidence of any
ntracranial bleeding was 0.05%/year, and the absolute rate
ncrease with ASA above placebo was 0.03%/year. Thus,
ompared with placebo, treatment with open-label ASA
ncreased the risk of major bleeding (relative risk [RR]:
.71; 95% CI: 1.41 to 2.08), major GI bleeding (RR: 2.07,
5% CI: 1.61 to 2.66), and intracranial bleeding (RR 1.65;
5% CI: 1.12 to 2.44). Despite randomization for baseline
atient characteristics, there might be unmeasured differ-
nces, and some of the patients—particularly older pa-
ients—might have a heightened risk of bleeding. Never-
heless, in patients at high risk for cardiovascular ischemic
vents, the relative benefit of ASA outweighs the risk of
leeding, particularly when lower doses are prescribed.
nlike the benefit for anti-ischemic effects, the risk of
SA-associated bleeding, particularly in the GI tract, seems
o be dose-dependent. A nonrandomized observation from the
RAVO trial of lotrafiban indicates that, when patients
reated with doses of 75 to 162 mg/day were compared with
hose receiving doses 162 mg, the risk of serious bleeding
as lower (2.4% vs. 3.3%), as was the likelihood of trans-
usion (1.0% vs. 2.0%, respectively) (11). Findings were
oncordant in a more recent observational analysis of
atients undergoing percutaneous coronary intervention
PCI) within the CURE (Clopidogrel in Unstable Angina
o Prevent Recurrent Events) trial for ACS. Patients were
tratified according to ASA dose (75 to 100, 125 to 175, or
200 mg/day). There was no evidence of difference in any of che ischemic composites according to dose, whereas the ad-
usted risk of bleeding was lower among patients treated with
he lower doses compared with the higher doses (hazard ratio
HR]: 2.03, 95% CI: 1.15 to 3.57). There also seemed to be an
nteraction with clopidogrel treatment; among patients in the
ower 2 dose ranges, the risk of bleeding did not increase after
reatment with clopidogrel, whereas among patients receiving
he higher dose, it did (3.3% for ASA alone, 4.5% for ASA
ith clopidogrel; HR: 1.39, 95% CI: 0.75 to 2.57) (12).
ual Antiplatelet Therapy
leeding risks have become more problematic with the
dvent of widespread and prolonged therapy with the
ombination of ASA and a thienopyridine (typically clopi-
ogrel) (1,9,13). Combination antiplatelet therapy with the
ovel third-generation thienopyridine prasugrel plus ASA
as associated with an increased risk of Thrombolysis In
yocardial Infarction major noncoronary bypass surgery-
elated bleeding events when compared with ASA plus
lopidogrel combination (2.4% and 1.8%, respectively; p 
.03) (14). Dual antiplatelet therapy provides incremental
latelet inhibition (compared with either agent alone) and
ore effective suppression of adverse ischemic events and
as been studied in the settings of medical therapy and PCI
s well as in stroke prevention and treatment.
The 2007 ACC/AHA clinical practice guidelines (15) for
he care of patients with UA/non–ST-segment elevation
yocardial infarction give a Class I indication for ASA to
e given immediately and continued indefinitely and for
lopidogrel to be administered and continued for at least 1
onth and preferably for up to 1 year after the index event,
egardless of whether a conservative or invasive treatment
trategy was initially selected. In patients in whom angiog-
aphy is performed and obstructive coronary disease is
dentified but who do not have revascularization, an oral
oading dose of clopidogrel (300 to 600 mg) should be
dministered, followed by 75 mg/day for at least 1 year. A
00-mg clopidogrel loading dose should be given the day
efore elective PCI to achieve effective platelet inhibition,
hereas a 600-mg clopidogrel regimen should be used if
ore rapid antiplatelet effect is needed (16).
Recommendations regarding duration of clopidogrel
herapy after ACS are based on observations from multiple
CTs, including the CURE trial, which enrolled 12,562
ubjects with UA or non–ST-segment elevation myocardial
nfarction (17). In CURE, subjects were randomly assigned
o receive either clopidogrel (300-mg oral loading dose,
ollowed by 75 mg/day) in combination with ASA or ASA
lone. Dual therapy was associated with a 20% RR reduc-
ion in the primary composite end point (MI, stroke, or
ardiovascular death) to 1 year of follow-up (from 11.4% to
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Combining Antiplatelet and Anticoagulant Therapies July 7, 2009:95–109.3%), findings that support early clopidogrel administra-
ion in patients managed with medical therapy, because the
schemic event curves diverge early in favor of clopidogrel.
owever, dual therapy was also associated with an excess in
ajor bleeding events (3.7% vs. 2.7%; p 0.003). Similarly,
n the post-randomization but pre-specified analysis of the
URE trial involving patients who underwent PCI (PCI-
URE) (18), a 31% RR reduction in the composite occur-
ence of cardiovascular death or MI at 1 year was observed:
rom 12.6% in subjects treated with ASA alone to 8.8% in
ubjects receiving dual therapy. The CREDO (Clopidogrel
or Recurrent Events During Observation) trial evaluated
utcomes in 2,116 patients after PCI. At 1 year, long-term
ual antiplatelet therapy with clopidogrel was associated
ith a 26.9% relative reduction in the combined risk of
eath, MI, or stroke (95% CI: 3.9% to 44.4%, p  0.02)
ersus ASA alone. (19). Although data from the COMMIT
ClOpidogrel and Metoprolol in Myocardial Infarction
rial) and CLARITY (Clopidogrel as Adjunctive Reperfu-
ion Therapy) trials extend only to 30 days, the parallel but
onger-term findings of the CURE, CREDO, and the
ubgroup with prior MI or stroke within the CHARISMA
Clopidogrel for High Atherothrombotic Risk and Ischemic
tabilization, Management and Avoidance) trial provide
vidence that clopidogrel’s effect is durable.
Conversely, it is important to remember that both the
resence and degree of benefit associated with dual anti-
latelet therapy are likely to depend on characteristics of the
pecific patient cohort. For example, the CHARISMA trial
tudied a population at risk for thrombotic complications of
therosclerosis but at a lower risk than patients in the
URE or CREDO trials. Although dual antiplatelet therapy
ASA plus clopidogrel) was not more effective than ASA alone
n the primary prevention cohort of the CHARISMA trial
patients with high risk profile but no established atherothrom-
otic disease), dual therapy was more effective in those patients
ith clinically evident cardiovascular disease at study entry
secondary prevention cohort) (20); at a mean follow-up of
7.6 months, the rate of cardiovascular death, MI, or stroke in
his secondary prevention cohort was significantly lower (6.9%
s. 7.9%, p  0.046) among patients assigned to dual therapy
ompared with ASA alone. However, moderate bleeding
vents were increased to 2% with dual therapy compared with
.3% with ASA only (HR: 1.60, 95% CI: 1.16 to 2.20,
 0.004).
Studies of dual therapy have demonstrated a variable but
verall increased frequency of bleeding events, possibly
nfluenced by both duration of therapy as well as ASA
osage. In a meta-analysis of 22 trials, ASA alone increased
he risk of major bleeding compared with placebo (RR:
.71, 95% CI: 1.41 to 2.08) (9). Although not all trials have mielded concordant results, in general, lower doses of ASA
100 mg) are associated with similar anti-ischemic efficacy
ut reduced bleeding event rates when given in combination
ith clopidogrel. Pooled analyses of multiple trials have
emonstrated a rough but direct relationship between ASA
ose and major and/or minor bleeding events, whereas no
dditional anti-ischemic efficacy has been seen with higher
oses; however, these data are limited by substantial differ-
nces in reporting of complications. The optimal dose of
SA to be used in combination with a thienopyridine
ould seem to be 100 mg (5,13,21,22).
ual Antiplatelet Therapy and Coronary Stenting
oronary stenting disrupts the endothelial lining and trig-
ers thrombin production, with subsequent deposition of
latelets and mural thrombi at the site of endoluminal
njury. Multiple RCTs (23) have compared different adjunc-
ive pharmacotherapy regimens in subjects receiving bare-
etal stents (BMS) (Table 2); study results have been
oncordant (24–28) and form the basis of the ACC/AHA
ecommendations for dual antiplatelet therapy.
The optimal duration of clopidogrel therapy after deploy-
ent of BMS has been controversial. Whereas an abbrevi-
ted regimen of 2 weeks has been suggested, longer treat-
ent (6 months) has been shown to provide benefits that,
lthough possibly unrelated to the stented site, might reflect
salutary effect of systemic treatment for a systemic disease
rocess (reduction in incidence of death, MI, or stroke)
19,29,30). There has also been recent recognition that both
ate (30 days to 1 year) and very late (1 year) thrombosis
ight complicate the use of BMS, particularly when de-
loyed for more complex (“off-label”) scenarios (18,31,32).
hus, in patients treated medically after presentation for
CS as well as those treated after PCI (BMS or DES),
xtended-duration dual therapy has demonstrated benefits,
nd care guidelines have correspondingly recommended
rogressively longer treatment durations. However, the
alance of reduction in thrombotic complications versus risk
f increased bleeding events in these patients remains poorly
efined.
Late thrombosis after DES implantation has catalyzed
ntense interest in defining an optimal duration of dual
herapy, thereby prompting a re-examination of the patho-
hysiologic mechanisms responsible for recurrent ischemic
vents after revascularization. Data from RCTs and regis-
ries were analyzed to formulate an AHA/ACC/SCAI/
merican Cancer Society/American Diabetes Association
cience Advisory (23), which recommends extending dual
ntiplatelet therapy for at least 12 months after DES
eployment and cautions that premature discontinuation
ight be associated with stent thrombosis and a consequent
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ecommends deferral of elective surgical procedures for at
east 1 year to accommodate dual antiplatelet therapy.
Studies comparing DES and BMS have shown that the
iming of stent thrombosis might differ (33–39). Stent
hrombosis tends to occur earlier in BMS, whereas stent
hrombosis in DES seems to trend later. Of particular
oncern is the observation that DES thrombosis might
ontinue to occur (albeit at a very low rate) over time (40).
n an attempt to prevent late thrombosis, a longer (possibly
ndefinite) duration of dual therapy is frequently recom-
ended, especially after DES in the setting of documented
evere extensive atherosclerotic disease.
These recommendations have important implications for
he subsequent performance of surgical procedures that require
topping antiplatelet therapy, which can lead to stent throm-
osis. Conversely, extended dual therapy prolongs the “window
f vulnerability” for bleeding, particularly in scenarios where
oncomitant warfarin might be necessary.
nticoagulant Therapy
arfarin monotherapy has been the mainstay of treatment
or patients with atrial fibrillation (AF), prosthetic heart
alves, markedly reduced left ventricular function or
eft ventricular thrombus, as well as for prevention or
reatment of deep venous thrombosis and pulmonary em-
olism. Randomized clinical trials have shown that warfarin
s superior to either ASA or clopidogrel for prevention of
troke in patients with AF, and observational data seem to
ave established it as the standard antithrombotic treatment
n patients with mechanical valve prostheses. Although
arfarin is currently indispensible in these settings, the
ombination of ASA and a thienopyridine is similarly
Table 2
After Bare-Metal Stent Placement, ASA Plus Thi
Reduces Cardiac Events Compared With ASA Al
Study (Ref. #) Patients Studied, n Patients Treated, n
ISAR (24) 517 626
FANTASTIC (25) 473 485
STARS (26) 1,653 1,965
MATTIS (27) 350 350
Hall et al. (28) 226 358
Cardiac death, acute myocardial infarction, or repeat target vessel revascularization at 30 days (e
nfarction, or stent occlusion at 6 weeks.
ASA  aspirin; ISAR  Intracoronary Stenting and Angiographic Results; MACE  major adve
TARS  STent Anti-thrombotic Regimen Study.ndispensible after stent implantation, and several random- ized clinical trials have shown the superiority of this com-
ination in patients who receive stents. A major clinical
ssue that is currently unresolved centers around the man-
gement of patients who have a firm indication for warfarin
herapy and who have received stents and thus also have an
ndication for dual antiplatelet therapy. This question is
articularly vexing among patients who have received DES
nd who, with the indication for long-term treatment with
ual antiplatelet therapy, have both a need for as well as
rolonged exposure to the risk of triple therapy. Unfortu-
ately, there are very limited data to provide guidance in this
rena, and the only randomized trials that offer any solace to
he perplexed clinician have compared combined warfarin
nd ASA with either warfarin or ASA.
Warfarin has also been evaluated in patients with recent MI
reated with warfarin versus placebo (but no ASA) (41). In this
rial, there was a reduction in risk of mortality of 24% (95% CI:
% to 44%, p  0.027). The combined incidence of major
leeding, however, was 0.6%/year. In the ASPECT (Antico-
gulants in the Secondary Prevention of Events in Coronary
hrombosis) trial (42), oral anticoagulant therapy alone after
I was associated with a 1.4% annual incidence of major
leeding versus 0.4%/year with placebo and with a significant
3% and 40% RR reduction of reinfarction (annual incidence
.3% vs. 5.1%) and cerebrovascular events (annual incidence
.7% vs. 1.2%) compared with placebo, respectively. Combi-
ation therapy of warfarin and low-dose ASA has also been
valuated in patients with ACS, mainly in survivors of acute
I. In the WARIS II (Warfarin-Aspirin Reinfarction Study)
43), APRICOT 2 (Antithrombotics in the Prevention of
eocclusion In COronary Thrombolysis 2) (44), and
SPECT-2 (Anticoagulants in the Secondary Prevention of
vents in Coronary Thrombosis) (45) trials, warfarin admin-
pyridine
or With Oral Antithrombins
MACE, %*
 Thienopyridine ASA  Warfarin ASA Only p Value
1.6 6.2 — 0.01
5.7† 8.6† — 0.37
0.5 2.7 3.6 0.0001
5.6 11.0 — 0.07
0.8 — 3.9 0.1
or the FANTASTIC [Full Anticoagulation Versus Aspirin and Ticlopidine] study). †Death, myocardial
diovascular events; MATTIS  Multicenter Aspirin and Ticlopidine Trial After Coronary Stenting;eno
one
ASA
xcept f
rse carstered with an international normalized ratio (INR) goal of 2.0
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Combining Antiplatelet and Anticoagulant Therapies July 7, 2009:95–109o 2.5 in combination with low-dose ASA, compared with
SA alone, was effective in reducing adverse ischemic events,
ncluding the composite occurrence of death or nonfatal
einfarction, as well as recurrent coronary occlusion after
T-segment elevation myocardial infarction. However,
hese trials also identified an increased risk of bleeding
ssociated with combination antiplatelet-anticoagulant ther-
py; in the WARIS-II trial, for example, 28 of 69 nonfatal
ajor bleeding episodes occurred in patients taking both
arfarin and ASA compared with 33 of 69 in patients
aking only warfarin and 8 in patients taking only ASA (43).
Indeed, combining warfarin with even a single antiplate-
et agent makes bleeding a more prominent concern. The
arfarin Antiplatelet Vascular Evaluation Trial investiga-
ors randomly assigned 2,161 patients with peripheral arte-
ial disease to receive either a single antiplatelet agent
choice of agent at physician’s discretion) in combination
ith warfarin (target INR 2.0 to 3.0), or antiplatelet therapy
lone (46). At a mean follow-up of 35 months, combination
warfarin plus antiplatelet) therapy was associated with
requent occurrence of fatal (0.9% vs. 0.3%), life-threatening
4.0% vs. 1.2%), intracranial (1.3% vs. 0%), and moderate
2.9% vs. 1%) bleeding events as well as with a more than
-fold higher incidence of the composite end point, which
ncluded life-threatening or moderate bleeding (6.9% vs.
.2%). Importantly, this trial defined moderate bleeding as
ntraocular hemorrhage or bleeding requiring transfusion of
to 3 U of blood products, whereas life-threatening
leeding was defined as either fatal, intracranial requiring
urgical intervention, or transfusion requiring 4 U of
lood products. Finally, combination therapy (vs. antiplatelet
herapy alone) did not significantly affect the incidence of the
omposite ischemic end point (cardiovascular death, MI, or
troke) that was observed in 12.2% and 13.3% of patients,
espectively (RR: 0.92; 95% CI: 0.73 to 1.16; p  0.48).
Testa et al. (47) used an adjusted indirect meta-analysis to
tudy the clinical outcome of combination therapy with
SA plus warfarin versus ASA alone. They identified 10
tudies that included 7,836 patients. In this group, Testa et
l. (47) demonstrated a significant 27% RR reduction of
ajor adverse events (death, MI, thromboembolic stroke) in
he combination group but a more than 2-fold increase in
ncidence of major bleeding events.
Bleeding risk with warfarin therapy has been the
ubject of intense interest in preventing stroke in patients
ith AF (48). The incidence of AF increases with age
nd greatly increases the risk of stroke. For patients with
F, warfarin therapy has proven superior for stroke
revention, compared with either ASA alone or dual
ntiplatelet therapy (49). However, the risk of bleeding
ith warfarin raises substantial concerns, particularly in ilder patients at risk for both bleeding as well as stroke
ue to AF. In a series of such patients 65 years of age,
major hemorrhagic event occurred in 7% during their
rst year of warfarin treatment (50).
Unfortunately, there is very limited information regard-
ng patients treated with triple therapy, who present signif-
cant clinical challenges because of the imperative to balance
leeding risks against risks entailed in stopping 1 of the 3
herapies. Discontinuation of warfarin might increase the
otential for stroke, whereas discontinuation of clopidogrel
ight result in increased risk for stent thrombosis; both
vents are associated with significant morbidity and mortal-
ty. Most available data have been derived from single-
enter registries or small case-controlled series or, in a few
ases, from post hoc analyses of prospective studies. Most of
hese studies focused on the risk of bleeding rather than the
ate of MI or stent thrombosis. Antithrombotic strategies
dopted in patients who require oral anticoagulation as well
s antiplatelet therapy can vary and are often left to the
udgment of the attending physician. In fact, indications
riefly reported on this topic by guidelines of the interna-
ional cardiovascular societies have a Class IIb recommen-
ation and a Level of Evidence: C (3–5). In published
tudies, the frequency and severity of bleeding events vary
ubstantially, possibly due to differences in bleeding defini-
ion, sample size, intensity of anticoagulant regimen, ASA
ose, and the clinical characteristics of the respective patient
opulations. Furthermore, in several of these reports, it has
roven difficult to discriminate patients who actually re-
eived triple therapy from those who received only a single
ntiplatelet agent plus warfarin.
In a study of 21,443 elderly patients after acute MI,
uresly et al. (51) evaluated bleeding complications associ-
ted with combination therapies including ASA, thienopy-
idine derivatives, and warfarin. Patients receiving ASA and
arfarin were at modest risk for bleeding (0.08/patient-
ear) compared with patients receiving ASA alone (0.03/
atient-year). A trend toward increased risk of intracranial
leeding was observed in patients treated with ASA and
arfarin, compared with ASA alone (11.1% vs. 6.4%, p 
.14). Only 141 subjects received triple therapy with ASA,
thienopyridine, and warfarin; just 1 bleeding event was
bserved among these patients. The small number of
ubjects and events in the triple therapy group precluded
alculation of an HR.
In a small retrospective study of triple therapy (n  66)
rom the Mayo Clinic PCI database for procedures per-
ormed from 2000 to 2002, no patients died or had stent
hrombosis, but 6 patients (9.2%) had a bleeding event (52).
f these, only 2 required transfusion, and there was nontracranial bleeding. Thus, although the risk of bleeding
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linical consequences. Of note, all bleeding events occurred
n patients with nonoptimal control of INR or pre-existing
I lesions, emphasizing the importance of bleeding risk
tratification and careful INR monitoring.
Similarly, Khurram et al. (53) observed increased bleed-
ng with triple therapy after coronary stenting in 107
atients with a mean follow-up of 211 days. Of note, 70%
f these patients had AF and 75% received a DES. Major
leeding was defined as bleeding that was significantly
isabling, intraocular, or required 2 U of blood products;
inor bleeding was defined as other bleeding events that led
o interruption of antiplatelet or anticoagulant therapy.
atients receiving triple therapy had more major bleeding
6.6% vs. 0%, p  0.014) and more minor bleeding (14.9%
s. 3.8%, p  0.01) compared with a control group of
atients who received dual antiplatelet therapy. Major
leeding complications in patients receiving triple therapy
ccurred 2 to 10 months after intervention. After adjusting
or confounding variables through multivariate analysis,
riple therapy was an independent predictor of bleeding,
ith an HR of 5.44 (p  0.001).
Mattichak et al. (54) evaluated 40 patients who under-
ent stent placement for acute MI and were treated with
riple therapy. This group was compared with 42 patients
ho received stents for acute MI but were treated with dual
ntiplatelet therapy. Significant differences in baseline char-
cteristics between the groups were observed: patients
reated with warfarin were older, had a higher frequency of
rior MI, and had a higher baseline creatinine. At 12
onths of follow-up, patients receiving triple therapy
howed a trend toward higher rates of GI bleeding (15% vs.
%, p  0.12) and more transfusions (21% vs. 3.5%, p 
.026).
More recently, Porter et al. (55) evaluated 180 patients
ho received PCI for an emergent or urgent indication and
ere subsequently treated with triple therapy. Although the
uration of therapy was only 30 days, 20 patients developed
leeding complications. In 18 of those patients, bleeding
as minor (defined as hematocrit decrease of 10% if
linical bleeding was observed or of 10% to 15% if no
linical bleeding was detected), and there were no intracra-
ial bleeds. Two patients developed major femoral access-site
ematomas related to the catheterization procedure itself.
fter 30 days, 104 patients continued treatment with only
arfarin and ASA; although the ASA dose administered in
his study was 100 mg/day, 19 patients had bleeding events (18
inor) and no intracranial bleeding was observed.
Nguyen et al. (56) evaluated 580 patients who underwent
tenting for ACS and were discharged on warfarin plus dual
ntiplatelet therapy as part of the GRACE (Global Registry if Acute Coronary Events) registry. At 6 months, a signif-
cant reduction in stroke was observed in patients receiving
arfarin plus dual antiplatelet therapy (0.7% vs. 3.4%, p 
.02). No differences in major bleeding events were ob-
erved in-hospital between patients receiving warfarin plus
ual therapy (5.9%) or those treated with warfarin and a
ingle antiplatelet agent (4.6%) (p  0.46). No follow-up
ata on bleeding events were presented. In the subset of
atients who received a DES (n  100), there were no
ifferences between treatment regimens in the hard end
oints of death, stroke, unscheduled PCI, or MI at 6
onths. However, patients receiving warfarin with single
ntiplatelet therapy had an absolute increased risk for
leeding of 2.7% during follow-up, but the total number of
vents was small and did not allow definitive conclusions to
e drawn.
A case-control study of 239 Finnish patients receiving
arfarin and undergoing PCI from 2003 to 2004 (57)
valuated a primary end point of death, MI, target vessel
evascularization, or stent thrombosis and a secondary end
oint of major bleeding and stroke to 12 months of
ollow-up. The most frequent indication for warfarin ther-
py was presence of AF, and triple therapy was used in 106
atients (48.4%). Stent thrombosis was observed more
requently (15.2%) among patients receiving warfarin plus
SA, compared with those receiving triple therapy (1.9%),
hereas stroke was more frequent in patients treated with
ual antiplatelet therapy only (8.8% vs. 2.8% with triple
herapy). Major bleeding (defined as hemoglobin decrease
f 4.0 g/dl, transfusion of 2 U of blood products, need
or corrective surgery, or intracranial or retroperitoneal
emorrhage) was similar between groups (6.6% triple ther-
py; 6.1% warfarin plus ASA; 11.1% warfarin plus clopi-
ogrel; and 11.8% ASA plus clopidogrel). Compared with
n age- and sex-matched control group, patients receiving
arfarin had a worse baseline cardiovascular risk profile, and
herapy with warfarin (combined with single or dual anti-
latelet agents) was an independent predictor of both major
leeding (8.2% warfarin vs. 2.6% no warfarin; OR: 3.3, 95%
I: 1.3 to 8.6; p  0.014) and cardiac events (death, MI,
arget vessel revascularization, stent thrombosis) at 1 year
21.9% warfarin vs. 11.0% no warfarin; OR: 1.7, 95% CI:
.0 to 3.0, p  0.05). Cardiac events were in large part due
o the higher incidence of stent thrombosis in the warfarin
lus ASA group.
Further observational data (58) from a series of 127
atients receiving warfarin (59% of whom had AF) who
ere treated with coronary stents and discharged on triple
herapy demonstrate a 7.1% total bleeding incidence (4.7%
ajor) during 21-month follow-up. Of note, major bleed-ng events were fatal in 3 (50%) cases and were intracranial
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hould, of course, be interpreted cautiously in light of the
mall number of events.
In a recent series of 426 patients with AF who received
tents, a variety of pharmacological strategies were evalu-
ted, with triple therapy being administered to 213 (50%)
atients (59). Adverse events were frequent (35%) in this
ohort, with major bleeding reported in 12.3% of patients;
ll-cause mortality was also high at 22.6%. Interruption of
arfarin therapy after intervention was associated with an
ncreased risk of cardiovascular events at a mean of 595 days
HR: 4.9, 95% CI: 2.17 to 11.09; p  0.01) and was largely
riven by thromboembolic complications. The clinical ben-
fit of continuing warfarin outweighed a 66% relative
ncrease in risk of major bleeding. In patients receiving DES
40% of the study population), there was no significant
ifference in the incidence of major adverse cardiac events
y multivariate analysis, although such patients had a
lightly higher rate of stent thrombosis (overall incidence,
owever, remained low). Unfortunately, no information on
leeding was provided for the DES cohort.
In aggregate, these studies illustrate the complex issues
acing those who attempt to formulate strategies for care of
atients treated with warfarin who also require dual anti-
latelet therapy. As noted in the preceding text, the most
ommon clinical scenario for such patients is AF with
oexistent CAD requiring a stent; patients with mechanical
rosthetic heart valves and concomitant CAD who require
stent comprise another important group. Some patients
ith deep venous thrombosis also require long-term anti-
oagulation, but in many patients, a duration of 3 to 6
onths will suffice. Approximately 45% of patients enrolled
nto these studies had ACS, DES were deployed in approxi-
ately 37%, and glycoprotein IIb/IIIa inhibitors were used in
ewer than 40%. Indeed, use of glycoprotein IIb/IIIa inhib-
tors might contribute to short-term bleeding risk after PCI.
he percentage of patients who undergo stenting and
equire concomitant long-term oral anticoagulation is likely
o increase because of the increasing number of PCI
rocedures and the advancing age of PCI patients (with an
ccompanying higher prevalence of related comorbidities).
n patients who require long-term oral anticoagulation,
erious consideration should be given to the use of BMS
rostheses for which dual antiplatelet treatment is recom-
ended for a shorter time after deployment.
Interpretation of data from published series is compli-
ated by the variability in treatment strategies, including
edication doses and duration of therapy, as well as
ariation in definitions used for bleeding events. Given the
ncreased frequency of AF among older patients and in-
reasingly widespread use of DES (for which dual antiplate- Cet therapy is recommended for at least 1 year), the issues
urrounding triple therapy will likely become even more
mportant. Considering the prevalence of AF, thought
hould be given to approaches that could help avoid the
eed for long-term warfarin, such as left atrial appendage
cclusion devices or pulmonary vein ablation. Left atrial
ppendage occlusion devices offer the potential to discon-
inue warfarin without increasing stroke risk and might
liminate the need for triple therapy in these patients (60).
n an initial experience of 66 patients with AF at increased
isk for stroke, warfarin could be discontinued in 90% of
atients; during follow-up of 740 341 days, there were no
trokes and only 2 transient ischemic attacks despite the
iscontinuation of warfarin.
The principal concern associated with triple therapy is
isk of bleeding or transfusion. The frequency of such
vents in reported series varies, with up to 21% of
atients needing a transfusion; bleeding events typically
nvolve the GI tract. This frequency might increase with
onger durations of triple therapy, which directly corre-
ate with bleeding risk and might influence mortality in
ollow-up after PCI. In particular, the RR of major
leeding in patients receiving triple therapy is 3- to
-fold higher than that observed in patients receiving
ual antiplatelet therapy alone. The increase in bleeding
vents is confounded by the fact that patients receiving
riple therapy are typically older and have multiple
omorbidities, which might increase bleeding potential.
oreover, limited use of triple therapy (for 1 month) is
ssociated with at least a 2-fold lower risk of major
leeding compared with prolonged use (6 months).
From these studies, it also seems that patients receiving
ual antiplatelet therapy only after PCI (prolonged warfarin
nterruption) have a 3-fold increase in incidence of stroke or
hromboembolic events, compared with patients receiving
riple therapy or warfarin plus a single antiplatelet agent.
urthermore, there are wide differences in the reported
ncidence of cardiac events during follow-up, probably due
o variation in antithrombotic regimens as well as in clinical
isk profiles, end point definitions, and length of follow-up.
owever, triple therapy was associated with a lower risk of
tent thrombosis and MI during follow-up; indeed, MI
uring follow-up might also result from stent thrombosis,
articularly in studies with higher rates of DES use.
revention of Bleeding in Patients
eceiving Maintenance Triple Therapy
or patients receiving triple therapy, the dose of ASA
hould be kept as low as possible (i.e., 75 to 81 mg).
lopidogrel should be given at its standard dose of 75
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July 7, 2009:95–109 Combining Antiplatelet and Anticoagulant Therapiesg/day, and warfarin should be administered under tight
ontrol to achieve a slightly lower target INR of 2.0 to 2.5.
here is growing international experience with “low-dose”
arfarin (INR 1.5 to 2.0) after low-profile, high-flow
echanical valve prostheses in the aortic valve position,
articularly in the context of normal ventricular function;
hromboembolic events are infrequently observed in these
atients. The prophylactic administration of proton-pump
nhibitors should be considered (10). Although recent data
ave identified a specific interaction with omeprazole,
hich might decrease platelet inhibition by clopidogrel (61),
he clinical significance of this interaction will be deter-
ined by an ongoing randomized, controlled clinical trial.
inally, if bleeding events occur or if GI bleeding risk is
igh, ASA may be discontinued. In this context, the change
n antiplatelet regimen most often linked to stent thrombo-
is or to the occurrence of death or MI after stent deploy-
ent has been discontinuation of the thienopyridine com-
onent of dual therapy (62–65).
atients Taking Warfarin and
ndergoing Evaluation for PCI
rug-eluting stents have been shown to be associated with
reduced need for target lesion revascularization in an
ncreasing number of angiographic patient subsets and are
ow the predominant percutaneous revascularization strat-
gy used in the U.S. Current guidelines recommend dual
ntiplatelet therapy for 1 year after DES. Therefore, the
hoices faced by the clinician caring for such patients are
ifficult. The operator implanting stents in patients who
ave a long-term need for warfarin should weigh the
otential bleeding risk against the risk and consequences of
estenosis in the stented site. In many cases, this balance
ight lead the operator to choose a BMS and commit the
atient to a short course of clopidogrel (4 to 6 weeks) in
ddition to ASA and warfarin, rather than to an extended
ourse of triple therapy. Given the risk of bleeding associ-
ted with triple therapy, BMS should be considered for use
n target vessels less likely to benefit from DES (e.g., vessels
3 mm in diameter, short lesions 15 mm, and de novo
tenoses). After deployment of BMS, duration of dual
herapy may be shortened considerably. Although regimens
s short as 2 to 4 weeks have been reported to offer adequate
rotection from early stent thrombosis with BMS, current
uidelines recommend approximately 3 to 6 months of
riple therapy, after which patients may continue on ASA
nd warfarin alone. Again, low-dose ASA (100 mg)
hould be considered to decrease bleeding risk.
One alternative for such patients is to place a DES for
reatment of very high-risk lesions and accept the small- to-moderate but definite increase in risk of bleeding. If
his strategy is chosen, warfarin should be administered
ith frequent monitoring so that the INR remains as
lose to 2.0 to 2.5 as possible, and low-dose ASA (100
g) should be given in combination with clopidogrel (75
g). Moreover, in patients with high bleeding risk
reated with DES for labeled indications, triple therapy
ay be limited to 3 to 6 months, with warfarin plus single
ntiplatelet therapy and a prophylactic proton-pump
nhibitor continued thereafter (10).
The single antiplatelet agent most effective in preventing
tent thrombosis and in reducing death or MI after coronary
tent thrombosis seems to be clopidogrel (39,57,62–65).
ide interindividual variability in responsiveness to clopi-
ogrel has been demonstrated with 15% to 31% (average 1
n 4) of patients being resistant to its effects on the basis of
latelet function testing (66,67). Recent data demonstrate
hat insufficient clopidogrel active metabolite generation is
he primary explanation for clopidogrel response variability
nd resistance (68,69). Variable levels of active metabolite
eneration associated with clopidogrel administration can
e due to limited intestinal absorption, which is determined
y efflux transported p-glycoprotein function that is affected
y polymorphisms of the ABCB1 gene or functional vari-
bility in cytochrome P-450 isoenzyme activity due to
rug–drug interactions and/or genetic polymorphisms of
YP450 isoenzymes (70,71). In this regard, the interaction
f lipophilic statins, rifampin, St. Johns’ Wort, and calcium-
hannel blockers with CYP3A4 (72–74); selected proton
ump inhibitors with CYP2C19 (61); and smoking with
YP1A2 (75) have all been reported to affect response to
lopidogrel. Indeed, the CYP2C19 drug–drug interaction
as been the putative explanation for attenuated clinical
fficacy of clopidogrel treatment observed during concomi-
ant administration of selected proton pump inhibitors,
pecifically omeprazole but not pantoprazole or esomepra-
ole (61,76). Recent studies have demonstrated an impor-
ant relationship between the relatively common presence of
reduced function CYP2C19 allele, impaired platelet inhi-
ition, and increased cardiovascular risk (71,77). These
tudies suggest that genetic testing might be an attractive
uture option used for personalizing antiplatelet therapy to
ptimize clinical outcomes. Furthermore, a recent study
uggests that the addition of genetic information to clinical
ariables to create a pharmacogenetic algorithm to guide
ral warfarin therapy provided a more accurate estimate of
ppropriate warfarin dose recommendations than could be
btained by either clinical variables alone or a fixed-dose
pproach (78). Hopefully, pharmacogenetic algorithms will
nhance the safety and efficacy of triple therapy regimens in
he future.
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Combining Antiplatelet and Anticoagulant Therapies July 7, 2009:95–109leeding in Patients Receiving Triple Therapy
leeding that occurs while patients are receiving triple
herapy is a particularly important problem. Management
ecisions are complex and might involve considerations of
atient acuity as well as the site and severity of bleeding.
evere or life-threatening bleeding usually requires reversal
f warfarin therapy. In rare instances, platelet transfusions
ight be needed to counteract concomitant thienopyridine
herapy. If dual antiplatelet therapy requires urgent discon-
inuation, the patient should be closely monitored, particu-
arly in the context of DES with their attendant risk of stent
hrombosis. Table 3 compares outcomes in patients receiv-
ng triple versus dual antiplatelet therapy plus oral antico-
gulation who underwent PCI (53,57,59,79–81).
In patients with mild or moderate bleeding, every effort
hould be made to maintain the INR as close to 2.0 as
ossible. In addition, ASA dose should be kept at100 mg.
f bleeding persists and anticoagulation is required (for
nstance, in patients with prosthetic heart valves, particularly
n the mitral position), there is limited information with
hich to guide therapy. The concern in this setting remains
he potential for valve or stent thrombosis. In particular,
nce bleeding is observed patients and practitioners might
e tempted to stop all antiplatelet medications in addition to
iscontinuing warfarin. In a registry series (57), stent
hrombosis was observed in 15.1% of patients treated with
arfarin and ASA, whereas there were no occurrences of
tent thrombosis in patients receiving warfarin and clopi-
ogrel. Whether this difference represents the play of
hance or reflects the relative importance of clopidogrel
ersus ASA in reducing stent thrombosis is unknown.
inally, strategies for reversing warfarin anticoagulation and
mploying interim anticoagulation with either unfraction-
Table 3
Follow-Up Clinical Results in Studies Comparing
Therapy Versus Dual Antiplatelet Therapy in Pati
Oral Anticoagulation and Undergoing Percutaneou
Outcome
Author (Ref. #)
Absolute Reduction of
Myocardial Infarction
Abso
Khurram et al. (53) NA
DeEugenio et al. (79) NA
Karjalainen et al. (57) 2.6%
Ruiz-Nodar et al. (59) 3.9%
Sarafoff et al. (80) 1.2%
Rossini et al. (81) 0%p  0.05; †Stroke  any thromboembolism.ted or low-molecular-weight heparin are largely untried
nd unstandardized. Interim heparin anticoagulation might
e used to “bridge” patients after acute treatment of the
leeding event and subsequent resumption of warfarin
herapy.
hanging Paradigms
ncertainties surrounding the optimal strategy for combin-
ng ASA, clopidogrel, and warfarin in patients treated with
ES who have an absolute indication for warfarin therapy
ill be further compounded by iterative changes in both
ntiplatelet and anticoagulation regimens that are likely to
ccur soon. Novel anticoagulant and antiplatelet regimes
ith more powerful antithrombotic potential are on the
mmediate horizon, as are stent designs that might prove
ess thrombogenic than current platforms, thus allowing
riefer durations of thienopyridine therapy.
hanges in Anticoagulant Drugs
ecause of difficulties inherent in warfarin monitoring,
uch as variations in dose response and multiple drug–
rug interactions, some have sought to replace warfarin
ith newer compounds that do not depend on vitamin K
ntagonism. The direct-acting oral thrombin antagonist
imelegatran was studied in patients with AF but was
bandoned because of concerns regarding serious liver
oxicity. Currently, a different direct antithrombin agent
dabigatran) is being evaluated in a similar patient pop-
lation, but how this novel compound will interact with
oncomitant ASA and thienopyridine therapy is unknown.
Attention has also focused on antagonists of activated
actor Xa as potential anticoagulants. The pro-thrombinase
omplex comprising Xa, FVa, calcium, and a negatively
ple
Requiring
oronary Intervention
Triple Therapy (vs. Dual Antiplatelet Therapy)
eduction
oke
Absolute Reduction
of Stent Thrombosis
Absolute Increase of
Major Bleeding
NA 6.6%
NA 11%*
4.0% 5.2%
*† 0.1% 5.9%
1.2% 1.7%
1% 0.9%Tri
ents
s C
With
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July 7, 2009:95–109 Combining Antiplatelet and Anticoagulant Therapiesharged phospholipid surface plays a crucial role in regulat-
ng the cleavage of prothrombin to thrombin (the “propa-
ation phase” of thrombosis). Inhibition of Xa theoretically
ould control otherwise explosive thrombin generation,
hile still allowing upstream generation of minute quanti-
ies of thrombin to provide some margin of control over
emostasis.
The Xa antagonist idraparinux, which can be adminis-
ered subcutaneously on a weekly schedule, was found to be
oninferior to warfarin for prevention of thromboembolic
vents in patients with nonvalvular AF but was associated
ith an increase in serious bleeding, including intracranial
emorrhage (82). This trial also discouraged enrollment of
atients who required antiplatelet therapy.
A variety of oral Xa antagonists currently being eval-
ated in clinical trials of patients with both AF and ACS
ffer greater insight into the safety of triple therapy
egimens that incorporate ASA, clopidogrel, and an Xa
ntagonist. In a recent study of the oral Xa antagonist
ivaroxaban, 3,491 subjects with ACS were stratified
ccording to whether they received concomitant ASA
lone or ASA and clopidogrel. Among subjects receiving
oncomitant ASA only, rivaroxaban therapy was associ-
ted with a modest increase in bleeding. Among subjects
eceiving the combination of ASA and clopidogrel,
owever, the composite bleeding rate increased from
.5% in the placebo group to approximately 15% among
hose receiving the highest dose of rivaroxaban and 6% at
he lowest dose (83). Similarly, in a smaller preliminary
tudy of the Xa antagonist apixaban administered to
atients with ACS, there was an apixaban dose-
ependent increase in bleeding observed among patients
eceiving concomitant ASA and clopidogrel, ranging
rom 3% (placebo) to 7% (low-dose apixaban) to 9%
high-dose apixaban). This gradient of bleeding events
as much less steep among patients receiving concomi-
ant ASA alone (84). Thus, although these novel agents
ight eventually replace warfarin, available data suggest
hat when they are administered in combination with
ntiplatelet therapies, bleeding risk will be increased.
hanges in Antiplatelet Drugs and Regimens
t is also likely that our armamentarium of antiplatelet drugs
ill change in the near future. Cloning of the target receptor
or clopidogrel and elucidation of the metabolic pathways
hat activate it have led to the design of “third-generation”
hienopyridines as well as nonthienopyridine P2Y12 recep-
or antagonists. These new agents act more rapidly than
lopidogrel and achieve a more profound blockade of the
eceptor. AOne such third-generation thienopyridine is prasugrel,
hich is converted to its active metabolite more efficiently
han clopidogrel and provides more rapid and intense levels
f P2Y12 blockade (85). Prasugrel was evaluated in the
ivotal TRITON–TIMI 38 (Trial to Assess Improvement
n Therapeutic Outcomes by Optimizing Platelet Inhibition
ith Prasugrel–Thrombolysis In Myocardial Infarction 38)
tudy, in which patients with ACS and planned PCI were
andomly assigned to treatment with either prasugrel
60-mg oral load, 10 mg/day) or clopidogrel (300-mg oral
oad, 75 mg/day). At a median follow-up of 14 months,
rasugrel was associated with a 19% reduction in the trial
omposite ischemic end point (cardiovascular death, MI, or
troke) and a nearly 52% reduction in stent thrombosis;
owever, an increased risk of major or fatal bleeding was
lso observed. A post hoc analysis revealed that most
leeding occurred in patients with advanced age (75
ears), low body weight (60 kg), or prior manifestations of
erebrovascular disease (transient ischemic attack or stroke)
86). Although prasugrel has not yet been approved by the
.S. Food and Drug Administration, it is likely to eventu-
lly find use in patients with high-risk ACS and possibly
fter complex stent placement. Although prasugrel has not
een studied in combination with oral anticoagulants, the
igher bleeding rate observed in combination with ASA (as
ompared with clopidogrel) makes it likely that adding
arfarin will incur an incremental risk for bleeding. A
horter-acting, reversible P2Y12 antagonist (AZD 6140) is
urrently being evaluated in clinical trials. Like prasugrel, its
ntiplatelet effect is more rapid and more potent than that of
lopidogrel, but unlike either agent, direct-acting AZD
140 does not require metabolic conversion (87) and has a
horter half-life (88), which might be advantageous when
sed in patients who also require warfarin.
Another class of antiplatelet drugs currently in develop-
ent are the antagonists of the primary human thrombin
eceptor, protease activated receptor (PAR)-1. This receptor
as sequenced and cloned in the early 1990s (89), and
ntagonists have been developed to block thrombin’s
latelet-activating effects. The SCH 530348 is an orally
dministered PAR-1 antagonist that has been evaluated in
hase II testing in patients with ACS who are undergoing
oronary angiography with planned PCI (90). In the pilot
tudy, therapy with SCH 530348 (vs. placebo) was initiated
n conjunction with ASA and clopidogrel before angiogra-
hy and continued for 60 days. Compared with placebo,
here was no difference in incidence of bleeding, but a
eduction in the composite end point of ischemic events was
bserved. Particularly encouraging was the apparent lack of
xcess bleeding in patients undergoing bypass surgery.
lthough SCH 530348 is being tested in larger phase III
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rom enrollment.
If SCH 530348 becomes clinically available, however,
nd does not increase bleeding risk, physicians could be
aced with the proposition of triple rather than dual anti-
latelet therapy. Although it is difficult to predict the degree
if any) of warfarin interaction with triple antiplatelet
herapy, it seems intuitive that the risk of bleeding during
ong-term “quadruple” therapy will likely be heightened.
onversely, if SCH 530348 proves effective and is associ-
ted with less bleeding, it could conceivably replace clopi-
ogrel among patients who require warfarin and in whom
SA is continued—a modified triple combination that
ould prove safer than the combination of clopidogrel,
SA, and warfarin. Finally, use of alternative antiplatelet
gents, such as the cyclo-oxygenase inhibitor triflusal—
hich is potentially associated with lower bleeding risk and
as been demonstrated as safe and effective in combination
ith warfarin in patients with AF (91)—could prove useful
n patients requiring oral anticoagulation and undergoing
CI; however, specific prospective, randomized studies are
eeded.
hanges in Stent Design and Technology
ew drugs cannot be considered in isolation from evolving
tent technology. The currently available data regarding
riple therapy after DES were gathered in patients treated
ith first-generation paclitaxel- and sirolimus-eluting
tents. Second-generation stents, including zotarolimus- or
verolimus-eluting platforms, have thinner struts and poly-
er coatings. Histopathologic studies in animals suggest
hat endothelial coverage of struts might be more complete
n vessels treated with these stents, which also seem to be
ssociated with less vascular inflammation (92). Conse-
uently, these stents could be less subject to late thrombosis
vs. first-generation DES) and might require shorter dura-
ions of dual antiplatelet therapy.
The next generation of DES will also likely employ
ioabsorbable polymers (93) that physiologically degrade
ver a period of months after drug elution; furthermore,
ully bioabsorbable stent platforms are being evaluated in
linical trials and might become available (94). The requisite
uration of dual antiplatelet therapy might be shorter when
uch bioresorbable devices are used. Similarly, stents de-
igned to capture circulating endothelial precursor cells
CD34 receptor-positive endothelial progenitor cells) might
romote vascular healing and undergo more rapid re-
ndothelialization, thus allowing shorter durations of dual
ntiplatelet therapy (95,96). The first generation of such
pro-healing” stents has undergone preliminary clinical
rials with follow-up through 2 years (97,98).onclusions
he combined use of antiplatelet and anticoagulant drugs
or the treatment and prevention of complications of 2 or
ore coexisting conditions, such as AF, mechanical valve
rosthesis, and/or a DES, is associated with an increase in
leeding complications that might range from mild or
oderate to severe or life-threatening. This risk increases
ith the duration of therapy, which should therefore be
imited to the time necessary for stent endothelialization in
atients at high risk for bleeding events. Before committing
patient to triple therapy for an indefinite period, the
hysician should carefully consider approaches that might
ot require prolonged dual antiplatelet therapy in conjunc-
ion with warfarin. For patients who require triple therapy,
areful follow-up is indicated, with low-dose (100 mg)
SA, conventional dose (75 mg) clopidogrel, a lower target
NR (approximately 2.0), and consideration of prophylactic
roton-pump inhibition.
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